-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Acumen Pharmaceuticals, Raises Price Target to $7

Benzinga·01/27/2026 10:02:36
Listen to the news
BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and raises the price target from $4 to $7.